JY BioMed defines research collaborations as joint scientific initiatives where we work with one or more external organizations to pursue mutually agreed research objectives. We strongly value collaborations that:

• Address significant unmet medical needs

• Advance fundamental or translational science in areas aligned with our platforms

• Leverage complementary expertise, resources, and technologies

• Maintain the highest standards of scientific integrity, transparency, and compliance

​

Depending on the nature of the collaboration, JY BioMed may contribute:

• Intellectual input and scientific consultation

• Access to investigational platforms, nonclinical data, or research reagents

• Limited financial or material support, subject to internal review and approval

​

Research partners may include, but are not limited to:

• Academic institutions and universities

• Clinical research centers and hospitals

• Cooperative research networks

• Biotechnology or pharmaceutical industry partners

• Government or non-profit research organizations

​

Research collaborations may be initiated by JY BioMed, by the external partner, or jointly through mutual discussion and agreement.

​

We are particularly interested in research collaborations focused on:

• Immune cell therapies (natural killer cells, gamma delta T cells, dendritic cell-based vaccines)

• Stem cell-based regenerative approaches (UC-MSCs, HF-MSCs)

• Exosome biology and therapeutic applications

• Target biologics (antibody-drug conjugates)

• Biomarker discovery, immune profiling, and translational models

​

Participation in JY BioMed research collaborations does not imply product approval or guarantee of clinical outcomes. All research activities must comply with applicable ethical guidelines, institutional policies, and regulatory requirements.